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Abstract 
The purpose of this quality improvement project was to develop an anemia management 
evidence-based intervention for patients receiving peritoneal dialysis (PD) and to educate staff 
on implementation of the anemia management protocol in a PD clinic in a southwestern county 
in Texas. Anemia is a common complication of chronic kidney disease (CKD) resulting from the 
inability of the kidneys to produce erythropoietin needed for red blood cell production. 
Erythropoiesis-stimulating agents such as Aranesp or Epogen may be administered to dialysis 
patients to stimulate erythropoiesis in the presence of kidney disease. Iron storage and iron 
availability remains imperative in effectively stimulating erythropoiesis for anemia management 
in the dialysis patient (Kliger et al, 2013). Anemia is one of the most common complications of 
CKD; over 48 million Americans have CKD attributing to millions with anemia of CKD origin 
(Centers for Disease Control and Prevention, 2017). A 6-month retrospective and current chart 
review of CKD patients’ undergoing PD was carried out at a PD clinic. An educational toolkit 
consisting of a pretest, anemia management protocol, and a post-test was developed and 
administered to staff. A patient educational toolkit consisting of instructional handout and a 
video was developed and administered to patients. Results indicated an improvement in staff 
knowledge about anemia management and an increase in patient hemoglobin and iron levels. 
This implementation was imperative to improving healthcare goals comparable with the Kidney 
Disease: Improving Global Outcomes (KDIGO) practice guidelines. 
 Keywords: anemia, peritoneal dialysis, protocols, evidence-based guidelines 
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Anemia Management for Patients Receiving Peritoneal Dialysis 
The kidneys are the major organ for erythropoietin production and are needed to 
stimulate the bone marrow to produce red blood cells. Erythropoietin is a glycoprotein produced 
by the kidney which stimulates red blood cell production (National Kidney Foundation [NKF], 
2017). When the kidneys start to fail, a condition called CKD may ensue.  
Chronic kidney disease is a “condition in which the kidneys are damaged or cannot filter 
blood as well as healthy kidneys” (Center for Disease Control [CDC], 2017, p. 1) and affects 
approximately 30 million people or 15% of the general population living in the United States 
(CDC, 2017).  Chronic kidney disease is exhibited by progressive irreversible nephron loss that 
is clinically manifested when 75% of nephron function is lost and decreases the organ’s ability to 
excrete wastes products, which, if left untreated leads to a high level of toxins in the blood over 
time (National Kidney Foundation [NKF], 2017).  
Chronic kidney disease can be classified into five stages based on the degree of kidney 
malfunction (National Institute of Diabetes and Digestive and Kidney Diseases [NIDDKD], 
2016). The stages of CKD are classified by an estimated glomerular filtration rate (GFR) which 
is the function of the kidneys based on age, sex, and body size (NKF, 2017).There are 5 stages of 
CKD: Stage 1 with a GFR of  >90ml/min; stage 2 with a GFR of 60-89ml/min; stage 3 with a 
GFR of  30-59ml/min; stage 4 with a GFR of 15-29ml/min; and the most serious stage, stage 5, 
also known as end stage renal disease (ESRD) with  a GFR < 15ml/min ( NIDDKD, 2016).   
According to the Centers for Disease Control and Prevention (CDC, 2017), diabetes and 
high blood pressure remain the leading cause of CKD and the primary cause of ESRD 
respectively. It further states that a total of 1 in 3 adults with diabetes and 1 in 5 adults with 
hypertension have CKD (CDC, 2017). Left untreated, CKD is progressive and may be fatal. 
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African Americans, Hispanics, Pacific Islanders, American Indians, and seniors are at increased 
risk for CKD (NKF, 2017). It is more common in women than in men. Additionally, 
approximately 48% of persons with “severely reduced kidney function” (CDC, 2017, p. 1) but 
not receiving dialysis do not know that they have the disease.  
Persons with stage 5 CKD or ESRD require some form of dialysis (hemodialysis [HD] or 
PD) to manage this chronic disease process, or a kidney transplant for a curative treatment 
(American Kidney Fund, 2018). Peritoneal dialysis is done in cycles inside the abdominal cavity 
where dialysis solution is exchanged through filtration and the waste is removed from the 
peritoneal cavity (NKF, 2017). This modality is often done in the patient’s home by the patient. 
Hemodialysis, on the other hand, is often done at a center where blood is removed from the body 
using an artificial kidney machine, the blood is cleaned by the artificial kidney and returned 
through connection tubes to the patient (NKF, 2017). It can also be performed in the patient’s 
home. The decision to utilize hemodialysis as opposed to PD is based on several dynamics and is 
not unique to one factor.  
One of the potential complications of CKD is anemia. Anemia is defined as reduced red 
blood cell concentration indicated by a low hemoglobin (Hgb) level and is generally diagnosed 
when the serum Hgb level falls below 12g/dL in women and less than 13g/dL in men (Amgen, 
2016; Stauffer & Fan, 2014).  Anemia is known to increase mortality, decrease physical 
functioning, and affect quality of life (Archer, Steinvoort, & Oderda, 2013). According to 
Stauffer and Fan (2014), in CKD, anemia may be associated with cognitive impairment, sleep 
disturbances, cardiovascular comorbidities, higher mortality, and CKD progression. Anemia 
related to CKD can be treated with iron and/or an erythropoietin stimulating agent (ESA) therapy 
to stimulate erythropoiesis (production of red blood cells) and improve Hgb and hematocrit 
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levels. Trials that examined the efficacy of ESA use in anemia indicated that two drugs, Epogen 
and Aranesp, are both effective erythropoietin analogs available to treat anemia in CKD and may 
prevent the need for blood transfusions (Archer et al., 2013). Aranesp has a longer half-life than 
Epogen and, therefore it is administered on a weekly basis compared to Epogen which is 
administered three times per week (McCausland et al., 2017).  
The 2012 KDIGO guideline also recommends the use of serum ferritin and transferrin 
saturation (TSAT) markers to define and evaluate iron stores and iron availability in treating 
anemia (Kliger et al., 2013; Macdougall, 2017). In addition to an ESA agent, the use of iron 
therapy such as Venofer is imperative for anemia management to maintain Hgb and should be 
commenced when TSAT is ≤ 30% and ferritin ≤ 500ng/ml (Kliger et al., 2013; Macdougall, 
2017).  Intravenous (IV) iron therapy is favorable to achieve and maintain acceptable ferritin and 
TSAT levels through erythropoiesis response, and this was supported by several studies in both 
hemodialysis and PD patients (Macdougall, 2017). The guidelines did not specify the type of IV 
iron to be used however, the cost is a variable in choosing an IV iron (Kliger et al., 2013). In 
addition to the cost, Venofer is also a component of the Center for Medicare and Medicaid 
Services (CMS) bundle in this PD clinic.  
Clinical Significance 
Anemia remains a clinically significant problem among patients receiving HD and PD 
and is known to impact the mortality and morbidity of CKD patients due to cardiac 
complications such as left ventricular hypertrophy and cardiovascular disease (Hörl, 2013). 
Anemia is estimated to affect 22% of patients with CKD stage 3 and 52% of patients with CKD 
stage 4 and increases the risk of mortality if it progresses to ESRD or stage 5 (McCausland et al., 
2017). Anemia related to CKD is caused by the kidney’s inability to produce adequate 
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erythropoietin, which can lead to low hemoglobin levels and possibly result in cardiovascular 
complications and an increased mortality rate. In dialysis patients, anemia is identified through 
frequent phlebotomy from laboratory studies including a complete blood count (CBC) and iron 
studies to include TSAT and ferritin (Rajaram, Himanshu & Pankaj, 2015).  
Anemia in CKD impairs a patient’s quality of life by exacerbating anemic symptoms 
such as fatigue, low energy, weakness and shortness of breath (Hörl, 2013). In addition, anemia 
exacerbates left ventricular hypertrophy and congestive heart failure related to hypoxemia and 
heart strain, which is common in the dialysis patient (Hörl, 2013). Dialysis patients diagnosed 
with anemia may need ESA therapy, iron therapy, or a blood transfusion(s) to correct the anemia 
(Charlesworth, Richardson & Battistella, 2014). Persons who receive HD or PD must be 
admitted to the hospital to receive a blood transfusion, which is in accordance with CMS 
regulations (CMS, 2017). The clinic that provides the dialysis services may sustain a financial 
loss when a patient is hospitalized for a blood transfusion because the clinic cannot bill for the 
patient’s dialysis treatment while the patient is hospitalized. Patients are known to incur the 
burden of hospitalization for a condition that could be managed on an outpatient basis with 
appropriate ESA and/or iron treatment instead of blood transfusion(s).  
Furthermore, CMS has implemented quality assessment and performance improvement 
measures (QAPI) to track and analyze patient outcomes continuously to achieve desired 
outcomes related to anemia. One of the quality indicators that CMS tracks is Hgb level; CMS 
stipulates that it should be maintained above 10g/dL every month in the dialysis patient. This 
tracking requires that dialysis centers report hemoglobin levels for every dialysis patient on a 
monthly basis (CMS, 2017). Successful management of anemia through the implementation of 
an outpatient anemia protocol based on clinical practice guidelines for ESA and/or iron therapy 
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significantly improves patient outcomes and can improve quality of life and adherence to dialysis 
treatment (CMS, 2017; National Kidney Foundation, 2017).  
Problem 
Anemia is a condition experienced by many patients with CKD who are receiving PD and 
is brought on by a reduction in the number of red blood cells. It is a contributing factor for 
structural heart damage and may lead to mortality in the advanced stages of CKD (Correa-
Gaviria & McCausland, 2017). In a study of 71,717 Medicare patients with CKD and anemia, 
there were strong indications that patients with Hgb less than 10g/dL were at higher risk of 
hospitalization compared to those with a hemoglobin of 11g/dL or 12g/dL (Hörl, 2013). In 
another study, CKD patients with a decrease in mean Hgb had increased mortality and cardiac 
complications along with symptoms of fatigue, low energy, weakness and shortness of breath 
(Hörl, 2013). Treatment of anemia with the prerequisite amount of iron and/or the use of an 
erythropoietin agent may subsequently improve these symptoms, could negate the need for a 
blood transfusion(s) which requires hospitalization, and may enhance patient quality of life by 
improving anemia (Correa-Gaviria & McCausland, 2017).  
When comparing costs of iron therapy and ESA therapy, it is noted that iron therapy costs 
Medicare $255 million while ESA therapy costs $1.8 billion in the ESRD population (Kliger et 
al., 2013). The cost of anemia management is important because CMS, the major payer for CKD 
services, has changed the payment of dialysis procedures to include a bundled payment for ESAs 
and iron. This has significantly affected how anemia is effectively managed in the dialysis 
patient because one bundled payment is expected to cover all aspects of patient care by the clinic 
(Kliger et al., 2013).  
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The specific problem that affects this PD clinic is that up to 48% of the patient population 
was not meeting the KDIGO guidelines for anemia management on a monthly basis. This 
information was obtained in a previous needs assessment done by the DNP student in the clinic. 
Furthermore, this is a new clinic without an anemia management policy or protocol to guide staff 
on how to improve and maintain patient’s Hgb levels.  
Review of the Literature 
PICOT Question 
The PICOT question that guided this inquiry is as follows: In peritoneal dialysis patients 
(P) how does an anemia management protocol in the dialysis clinic (I) compared to not having an 
anemia management protocol (C) improve staff ability to manage anemia outcomes?  
The search strategy included searching the CINAHL database, accessed through the UIW 
library. Google scholar was also used to access publications dated January 2013 to April 2018.  
Key terms and phrases used were anemia in CKD, management of anemia, CKD, PD, anemia 
goal, goal of Hgb level, patient teaching and effective patient teaching methods. The results 
yielded multiple publications which were narrowed down and selected based on relevance and 
evidence-based. 
In the CKD patient who is receiving dialysis treatment, the target Hgb is 10-11g/dL. The 
pathogenesis of anemia in CKD is associated with decrease erythropoietin (EPO) production by 
the kidneys, iron deficiency, inflammation, and EPO resistance (McCausland et al., 2017). 
Anemia in CKD worsens and further reduces kidney function if left untreated (McCausland et 
al., 2017). Additionally, it  can contribute to left ventricular dysfunction, increase morbidity, and 
cause low energy, breathlessness, dizziness, angina, poor appetite, and exercise intolerance 
(Hahn, Cody, & Hodson, 2014). ESAs and IV iron are the primary treatment for anemia in CKD 
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to improve anemic symptoms and increase Hgb (Hung, Lin & Tarng, 2013). Common 
comorbidities of CKD are weak bones, poor nutrition, nerve damage, heart and blood vessel 
diseases, as well as anemia (NKF, 2017). 
Kidney Disease: Improving Global Outcomes (KDIGO) is a global non-profit foundation 
that aims to improve patient care and outcomes internationally through coordination, 
collaboration, and initiatives to create and implement practice guidelines for the kidney disease 
patient.  In 2012, the KDIGO clinical practice guidelines for anemia provided guidance on 
management and treatment for all CKD patients at risk for developing anemia. The guidelines 
stated that ESA is safe and effective treatment for erythropoietin-deficient anemia and should be 
administered with a baseline Hgb of less than 10g/dL so that Hgb can be increased and 
maintained at 11g/dL but not above 11.5g/dL. This guideline is in support of the Normal 
Hematocrit Study which indicated that dialysis patients with target Hgb of 11-13g/dL had worse 
outcomes when compared to those with a Hgb of 9-11g/dL (Kliger et al., 2013).  Specifically, 
those with a Hgb of 11-13g/dL experienced increase cardiovascular disease and increase risk of 
stroke. 
ESA therapy is significant in reducing the need for blood transfusion related 
hospitalizations and reduces erythropoietin-deficient related anemia symptoms (Kliger et al., 
2013). ESA therapy eventually decreases the cost and burden associated with blood transfusions 
and hospitalizations. ESA therapy improves patient quality of life and increases patient safety by 
improving symptoms (Kliger et al., 2013). Archer et al. (2013) also recommends ESA use in the 
treatment of erythropoietin-deficient anemia for dialysis patients experiencing CKD and 
advocates using agents such as Epogen/Erythropoietin (EPO) and Aranesp with an acceptable 
risk-benefit. Aranesp, which is administered subcutaneously or intravenously, is the more 
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favorable therapy of the two ESAs used to treat anemia related to chronic kidney disease in PD 
and HD patients. Aranesp has a 3-fold longer half-life when administered compared to EPO; as a 
result, it is given weekly while EPO must be administered three times per week (Archer et al., 
2013). Additionally, patients can be instructed to self-administer Aranesp, or caregivers can be 
taught the administration process, thus reducing the need for a clinic visit.  
Besides low red blood cell production, CKD dialysis patients may exhibit anemia caused 
by low iron levels. Iron agents can be used alone or in combination with an ESA to maintain 
anemia at a desirable level. Iron agents must be used to treat patients when transferrin saturation 
(TSAT) is ≤ 30% and ferritin level is ≤ 500ng/ml. A TSAT and ferritin level must be obtained 
when a Hgb level is required to determine if management with an ESA and/or an iron agent is 
indicated (Kliger et al., 2013).   
In a multicenter, open-label study of 101 patients with CKD who were HD dependent, 77 
patients received Venofer treatment and 24 patients were followed in the control group 
(American Regent, 2015). The results indicated that patients in the Venofer treated group 
showed a greater increase in Hgb and hematocrit than the patients in the control group. The 
ferritin and TSAT levels also increased in the Venofer group when compared to the control 
group (American Regent, 2015).   
In another study conducted by American Regent (2015), a randomized, open-label 
multicenter trial compared PD patients receiving EPO and IV iron to those receiving EPO alone. 
The patients who received Venofer and EPO (59.1%) had an increase in Hgb of ≥ 1 g/dL during 
the study compared to the patients who received EPO only (33.3%) (American Regent, 2015). 
Due to the overwhelming literature supporting the use of an ESA and/or an iron agent, it is 
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imperative to develop and implement measures supportive of the findings to improve anemia 
among CKD patients in the clinical setting (Macdougall, 2017).  
Anemia management protocols (AMPs) should guide ESA and iron dosing for effective 
management of patients with CKD (Kliger et al., 2013). In four clinical trials conducted by major 
drug companies, Hgb was maintained using dosing algorithms and a dosing protocol 
(Charlesworth et al., 2014). The dosing algorithms were designed to achieve and maintain Hgb 
levels at the desired target. The protocol specified dose adjustments were designed to follow the 
dosage administration and were successful in maintaining Hgb in the target range of 10-12g/dL 
(CMS, 2017). A retrospective observational study in 174 patients conducted over 6 months 
implemented an Aranesp dosing anemia protocol. The results indicated that the use of an anemia 
management protocol resulted in decreased prescribing of Aranesp and iron while increasing 
patients target Hgb range to an acceptable level of 10-12g/dL (Charlesworth et al., 2014). 
In another study by Pirkle, Paoli, Russell, Petersen and Burkart (2014), 139 PD patients 
received Aranesp and IV iron for anemia management protocol. The study found that patients on 
the anemia management protocol maintained stable Hgb levels between 10-12g/dL using 
Aranesp and IV iron. This treatment intervention is inconsistent with the current KDIGO anemia 
management guidelines of maintaining Hgb at 10-11.5g/dL. In addition, the anemia protocol 
might improve Hgb outcomes including identification and treatment of CKD patients with 
anemia and increase patient responsibility in administering an injectable medication at home 
(Pirkle et al., 2014). 
 Patient teaching remains imperative to patient care and is a significant aspect of the 
home dialysis patient (Schaepe & Bergjan, 2015). Among the patient teaching strategies, patient-
centered videos have proven to foster better memory and are more practical for patient learning. 
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Friedman, Cosby, Boyko, Hatton-Bauer, and Turnbull (2011) examined systematic reviews of 
the effectiveness of videos on patient education outcomes and 13 of 22 studies indicated 
increased patient knowledge and greater satisfaction for the patient intervention. In addition, 
written materials created at a reading level for the general population combined with verbal 
health information significantly improved knowledge (Friedman et al., 2011).  As a result of 
these findings, the patient education aspect of this quality improvement project will be developed 
on the foundation of these teaching strategies. 
In another study, Marcus (2014) examined verbal education in a 150-bed community 
hospital. It was concluded that though one on one patient teaching is effective it needs to be 
individualized taking into consideration, patient culture, literacy level, and effective 
communication. It also concluded that verbal education should not be the only method of patient 
teaching.  Furthermore, effective patient education practices must be learned and reinforced by 
staff educators, and an assessment is recommended using a teach-back tool (Marcus, 2014). 
  Finally, Smith and Zsorhar (2013) suggested other effective patient teaching methods 
including computer-aid teaching, video education, demonstration, return demonstration, teach 
back or tell back, and written materials with pictures. These methods have proven to improve 
patient learning; however, individualization of patient teaching is of utmost importance (Smith & 
Zsorhar, 2013).  
Methodology 
 The needs assessment conducted by the DNP student indicated that the clinical practice 
guideline to maintain Hgb at an acceptable goal was nonexistent in this clinic. There was no 
established anemia protocol and the clinical management skills and expertise are not unique to 
policy development. Furthermore, staff and stakeholders including the nurse practitioner and 
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nephrologist expressed the need to implement a successful anemia management protocol in the 
clinic and gave approval for this project (Appendix A). In addition, there were 27 established 
patients in the clinic, and of that number only an estimated 50% had reached the Hgb target of 
10g/dL in the past 6 months. There was also a gap in patient education in self-administering 
Aranesp at home. As a result, there was a need for staff and patient education to increase and 
maintain Hgb level at the target range. This quality improvement project was appropriate for the 
organizational plan to maintain a high standard and a routine standard of care in accordance with 
CMS guidelines. In addition, this project encompassed the DNP essentials in using evidence-
based data to develop and implement a quality improvement project aligned with the knowledge 
and expertise of the DNP graduate (American Association of Colleges of Nursing [AACN], 
2006).  
Design 
This project was a quality improvement project that utilized the KDOQI guidelines to 
develop an evidence-based anemia management protocol administered by staff to the dialysis 
patients ages 18 to 75 years cared for at the dialysis clinic and included a patient education 
program related to anemia management. 
Setting 
The setting was a standalone PD clinic located in the southwestern United States. The 
clinic was established in 2016 and received CMS approval, and serves clients from a multicounty 
rural area. The clinic was made up of 5 exam rooms, a patient waiting area, and a patient 
education room. Patients were seen at the clinic at least on a monthly basis and visit once weekly 
for lab draws and any other treatment interventions such as Venofer administration. Patients 
were also seen by the nurse in their homes to provide teaching on PD administration, assessment 
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of patient condition, environment and potential or actual complications. The medical assistant 
saw patients in their homes to replenish supplies and obtained lab draws when indicated. 
Therefore, the patients home and home environment were considered an extension of the setting.  
Risk Analysis  
The university IRB approved this project prior to implementation. There were no risks 
involved in this quality improvement project as an evidence-based guideline was implemented.  
Furthermore, the majority of the participants have diabetes and were receiving insulin injections 
with a similar administration technique as that used for Aranesp. All patients’ allergy records 
were reviewed for contraindications of Aranesp or Venofer  before any medication 
administration was initiated. 
Sample 
This project targeted the staff of the clinic including the two registered nurses and the 
medical assistant (MA) as well as the 24 clinic patients who were receiving PD as of February 
2018 and were not already participating in a research study.  
Intervention 
 This project included an intervention for staff related to the anemia protocol 
implementation and a patient education intervention as described below. 
 Staff education interventions. Objective 1: By the end of February 2018, 100% of staff 
would increase their knowledge in managing anemia using evidence-based anemia protocols for 
the dialysis patient at the clinic. Implementation plan: 
1. A pre-test on anemia management was administered to the registered nurses and MA in 
February 2018. The pre-test was developed by the DNP student according to definitions and 
guidelines from the KDIGO guidelines (Appendix B). 
ANEMIA MANAGEMENT FOR PATIENTS   20 
 
2. Following the pre-test staff educational materials and instructions regarding the anemia 
management protocol were developed and provided to staff via an in-service conducted by 
the DNP student at the dialysis clinic in February 2018. The protocol and educational 
materials were also placed in a centralized location at the desk readily available to staff for 
easy access as well as in the electronic medical record (EMR) under policy and procedure. 
Details of the protocol included the Aranesp dosing guideline which was developed by the 
DNP student using the guideline designed by Amgen pharmaceutical for the medication and 
is comparative to the KDIGO guidelines (see Appendix C). The Venofer dosing protocol (see 
Appendix D) was also designed by the DNP student using the KDIGO guidelines; the anemia 
clinical practice guidelines were both based on systematic reviews on managing anemia and 
are used globally (Kliger et al, 2013). The protocols were approved by the nephrologist and 
the charge nurse. 
Outcome. 100% of staff (registered nurses, MA) should increase their knowledge up to 
at least 90% related to anemia management as measured by a written pre and post-test designed 
by the DNP student and administered before the in-service and approximately 2 weeks after the 
initial in-service (see Appendix B). 
Evaluation. The pre-test was administered before the initiation of the educational 
intervention (Appendix B) and given approximately 2 weeks after the in-service to evaluate the 
effectiveness of staff educational intervention.  
Patient education interventions. Objective 2: By the end of April 2018 all patients will 
have reviewed the Aranesp administration video and teaching materials. 
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1.The DNP student instructed the registered nurses and the MA to administer the educational 
pamphlet and video regarding Aranesp administration via the patient iPad or television that 
was available in the clinic education room.   
2. Each patient was to receive an anemia patient educational pamphlet (see Appendix E) at 
their weekly appointment, sourced from Amgen pharmaceutical patient education. The 
pamphlet consisted of basic information about anemia, taking medication for anemia and 
stepwise instructions on administering Aranesp (see Appendix E). These instructions were 
created by Amgen for patient educational purposes with no stated reliability and validity 
(Amgen, 2017). The handouts were available in both English and Spanish.  
3. Each patient would be asked to watch the 13-minute video (see Appendix F) via the iPad 
or television during a regular scheduled clinic appointment.  
4. At the end of the video, the patients were to be given the Aranesp medication to self-
administer if indicated by Hgb level according to the protocol while the staff member 
observed the administration.  
5.The staff were instructed on utilizing the patient teach-back tool to assess patient 
competency and mastery of the Aranesp injection procedure (see Appendix G). The purpose 
of this tool was to document that the patient received the educational intervention and 
demonstrated self-administration of Aranesp. 
Outcome. All patients should view the Aranesp medication video and educational 
information and demonstrate to staff the injection process.  
1. The nursing staff should observe all patients to verify that there was a 100% 
demonstration of the correct administration technique of Aranesp and to provide 
feedback on administration technique.  
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Evaluation. The Teach-Back tool was used by staff to evaluate the stepwise process of 
the patient self-administering Aranesp correctly (Appendix G). No psychometric properties of 
reliability and validity were available on this tool; however, it was used by the Agency for 
Healthcare Research and Quality (AHRQ) to improve patient understanding and adherence of a 
learning activity (AHRQ, 2015). 
Objective 3: By the end of April 2018, patients’ Hgb level would be maintained at the acceptable 
clinical goal of 10-11g/dL, with a TSAT of 30% -50%.  
Interventions. Staff would utilize the anemia management protocol consisting of an 
Aranesp protocol (see Appendix C) and the Venofer protocol (see Appendix D) to manage 
patient anemia immediately after the in-service was provided in February 2018. 
Outcome. By the end of April 80% of patients included in the sample (N = 24) should 
have a Hgb level of 10-11g/dL, with a TSAT of 30% -50%.  
Evaluation. The DNP student used the demographic chart review tool (see Appendix H) 
to obtain and assess patient Hgb and TSAT levels after the staff had begun implementing the 
protocols. These levels were compared with the pre-intervention levels to determine appropriate 
use of the protocol and assess patient response to the protocol treatments in the form of 
laboratory findings.  
Data Collection 
 Chart review: The DNP student reviewed patient records pre and post-intervention from 
December 2017 to April 2018 by the DNP student.  The data retrieved included patient age, sex, 
ethnicity, marital status, Hgb levels and iron levels (TSAT and ferritin level).  Additional 
characteristics such as language spoken were included. The instrument used to collect this data is 
located in (see Appendix H). No patient identifying information was extracted. 
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Data Analysis 
Descriptive statistics were calculated for adherence to anemia management protocols. 
Specifically, percentages were calculated for number of patients grouped by Hgb and iron levels, 
percent that needed protocols, percent that received protocol implementation, and number of 
patients whose Hgb or iron levels improved after receiving the protocol treatment(s). Percent of 
patients who received patient education was calculated as well. 
Results and Findings 
Regarding objective 1: By the end of February 2018, 100% of staff would increase their 
knowledge in managing anemia using evidence-based anemia protocols for the dialysis patient at 
the clinic. 
By the end of February 2018, 100% of staff increased their knowledge in managing 
anemia using evidence-based anemia protocols in the dialysis patient at the dialysis clinic after a 
DNP led in-service on a new anemia protocol and implementation of the protocol. This finding 
was assessed via the pre and post-test (Appendix B) 
Three staff members, two nurses and a MA completed the intervention. One nurse scored 
10/10 on both pre-test and post-test, the other nurse and medical assistant scored 9/10 and 7/10 
respectively on the pretest and 10/10 and 9/10 respectively on the post-test indicating an increase 
in knowledge related to managing anemia.  
 Regarding objective 2: By the end of April 2018 all patients will have reviewed the 
Aranesp administration video and teaching materials. 
The DNP student verified that staff members were implementing the video and teaching 
materials via chart reviews and observed at least 1 teaching session performed by each staff 
member.  The 3 staff members performed the teaching session 100% correctly. The two 
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registered nurses were observed by the student in using the Aranesp protocol to dose Aranesp 
and observed staff in their observation and feedback given to patients in self-administration of 
the medication in a stepwise manner as shown in the video. The DNP student observed the two 
registered nurses in dosing patients’ Venofer based on their ferritin and iron levels during the 
comprehensive clinic visit and this was done accurately. The 24 patients received the educational 
hand out and watched the Aranesp video. Seventeen patients were required to complete return 
demonstration of Aranesp administration. Among these 17 patients 53% or 9 of the patients 
demonstrated the administration steps 100% correctly, and 17.6% or 3 demonstrated the 
administration steps 80% correctly and 5 or 20.8% were not observed because they did not 
require Aranesp administration. 
Regarding objective 3: By the end of April 2018, patients’ Hgb level would be maintained at the 
acceptable clinical goal of 10-11g/dL, with a TSAT of 30% -50%. 
After the protocol implementation, 15 dialysis patients or 62.4% had a Hgb at goal and 
20 or 83.3% had a TSAT at goal by the end of April. 
The demographic characteristics of the 24 dialysis recipients is shown in Table 1. The 
patients (N = 24) were 50% males (n = 12) and 50% females (n = 12). Their age ranged from  25 
to 75 years with a mean age of 58.7 years. Three patients were between the ages of 25 to 44 
years, 12 were between the ages 45 to 64 years and 9 were over the age of 65 years. The 
ethnicity of the dialysis recipients consisted of 71% Hispanics (n = 17), 25% non-Hispanic 
Whites (n = 6), and one patient’s ethnicity was listed as Non-Hispanic. Eleven of the participants 
were married, two single, one common law marriage, one separated and 9 patients did not have 
their marital status documented. Fifty-eight percent (n = 14) of the patients had Medicare 
insurance, 42% were covered by private insurance (n = 10) and 8% (n = 2) had both Medicare 
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and private insurance. Sixty-six percent or two-thirds of the patient sample (n = 16) had some 
form of diabetes and were receiving medication for diabetes management.  After diabetes, the 
second most frequent co-morbid diagnosis was hypertension which was noted in one-third or 8 
of the 24 participants. 
Table 1 
 
Demographic Data 
 
Sex Participants Percentage % 
Female 12 50 
Male 12 50 
Age  
25-44 years 3 12.5 
45-64 years 12 50 
65 years and older 9 37.5 
Ethnicity   
Hispanic 17 71 
White 6 25 
Non-Hispanic 1 4 
Marital Status   
Married 11 45.8 
Single 2 8.3 
Common Law 1 4.1 
Separated 1 4.1 
Not Stated 9 37.5 
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Regarding objective 4: By the end of April 2018, patients’ hemoglobin level would be 
maintained at the acceptable clinical goal of 10-11g/dL, with a TSAT of 30% -50% and ferritin 
level of 100-500ng/ml.  
The 24 patient records were reviewed and information concerning hemoglobin level, 
TSAT, ferritin level, and whether Aranesp and Venofer protocol were indicated and 
implemented was extracted to determine adherence to the treatment protocols. The results are 
displayed in Table 2.  
Based on data from table 2, the following findings were noted. In December 2017, nine 
of the 24 patients or 37.5% had a Hgb level below 10g/dl, 29% (n = 7) had Hgb levels of 10g/dL 
or greater, and 33.3% or eight patients had no Hgb levels documented. Four patients or 16.6% 
had a TSAT level above 30% (the targeted range), 50% (n = 12) were below 30%, and 33.3% (n 
= 8) had no TSAT results documented. A total of 8.3% (n = 2) had ferritin levels below 
100ng/ml, 50 % (n = 12) had ferritin levels above 100ng/ml and 41.6% (n = 10) had no results 
documented due to no lab draw from the patient either due to hospitalization or no show for 
blood work. 
In January 2018, 37.5% (nine patients) had a Hgb level below 10g/dL indicating that they 
were experiencing anemia, 37.5% (nine) were above 10g/dL (the targeted range), and 25% (six 
patients) had no results. Five patients or 20.8% had a TSAT of 30% and above, 54.1% (thirteen 
patients) had a TSAT below 30%, 25% or six dialysis recipients had no results and 25% (six 
patients) who had TSAT levels below target also had low Hgb levels, during the same period. 
Reasons that no results were documented may include patient hospitalization or no show for lab 
draw.  
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Table 2 
Patient’s Laboratory Values Before and After Protocol Implementation 
Pt Date Hgb TSAT % Ferritin Venofer mg Aranesp 
mcg 
Dosage Protocol 
used  
Note 
1  Dec-17 
 
9.4 73 1566 No No NA No  
Jan-18 
 
8.4 
 8.2 
104 
----- 
1540 
------- 
No No NA No Pt 
Refuse  
Feb-18 6.8 
7.8 
57 
----- 
1332 
------- 
No Yes 100mcg PI: A  
Mar-18 
 
8.8 
9.0 
23 
----- 
1252 
----- 
No Yes 100mcg PI:A  
Apr-18 10.5 49 1306 No No NA Yes  
2  Dec-17 
 
11.1 21 356 
 
No No NA No  
Jan-18 
 
11.3 28 369 No No NA No  
Feb-18 
 
9.7 21 478 Yes Yes 40mcg 
300mg 
PI:A 
PI:V 
 
Mar-18 
 
10.0 ------ ------- No No NA Yes  
Apr-18 11.0 28 621 No No NA Yes  
3  Dec-17 
 
---- 
 
----- ---- No No NA No  
Jan-18 
 
---- 
 
---- ----- No No NA No  
Feb-18 
 
10.3 21 484 Yes Yes 300mg 
40mcg 
PI:V 
PI:A 
 
Mar-18 
 
10.2 33 414 No No NA Yes  
Apr-18 10.5 32 337 No No NA Yes  
4  Dec-17 
 
8.6 
 
11 
 
200 
 
Yes Yes 100mg 
100mcg 
No  
Jan-18 
 
10.3 
 
21 
 
238 
 
No Yes 40mcg No  
Feb-18 
 
11.7 
 
25 
 
332 
 
No No NA PI  
Mar-18 10.6 24 236 No No NA Yes  
Apr-18 11.4 22 138 No No No Yes  
5  Dec-17 
 
---- ---- -----    NA  
Jan-18 
 
---- ----- ------    NA  
      (continued) 
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(continued)     
Feb-18 
 
10.8 18 664 Yes No 300mg PI:V  
Mar-18 
 
12.4 23 575 No No NA Yes  
Apr-18 11.9 27 241 No No NA Yes  
6  Dec-17 
 
----- ------ ------      
Jan-18 
 
9.6 8 1151 No No NA No  
Feb-18 
 
12.3 18 871 No No NA PI  
Mar-18 
 
11.7 25 718 No No NA Yes  
Apr-18 13.1 22 615 No No NA Yes  
7  Dec-17 
 
11.4 23 791 No No NA NA  
Jan-18 
 
11 27 859 No No NA NA  
Feb-18 
 
10.3 23 783 No Yes 25mcg PI:A  
Mar-18 
 
9.5, 
9.3 
21, 20 758, 765 Yes Yes 100mg 
60mcg 
PI:A 
PI:V 
 
Apr-18 10.0 16 771 Yes Yes 100mg 
60mcg 
PI:V 
PI:A 
 
8  Dec-17 
 
9.6 35 315 No No NA No  
Jan-18 
 
8.0 21 402 No No 25mcg No  
Feb-18 
 
7.8 19 229 No Yes 100mcg PI:A  
Mar-18 
 
10 24 174 No Yes 100mcg PI:A  
Apr-18 ----- ---- ----     Hospit
alized 
9  Dec-17 
 
----- 
 
----- 
 
------ 
 
 
 
 
 
 
 
  
Jan-18 
 
8.5 14 
 
199 No  No NA   
Feb-18 
 
8.2 8 340 No No NA PI  
Mar-18 
 
9 7 895 Yes No 300mg PI:V  
Apr-18 9.6 33 419 Yes Yes 300mg 
60mcg 
PI:V 
PI:A 
 
           
        (continued) 
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  (continued)     
10  Dec-17 
 
---- ----- ------      
Jan-18 
 
---- ----- ------      
Feb-18 
 
10.7 11 191 No No NA PI  
Mar-18 
 
10.7 18 180 Yes Yes 300mg 
25mcg 
PI:V 
PI:A 
 
Apr-18 11.6 20 287 No No NA Yes  
11  Dec-17 
 
----- ----- ------      
Jan-18 
 
----- ----- ------      
Feb-18 
 
9.4 36 244 No No  PI  
Mar-18 
 
8.6 15 283 Yes No 300mg PI:V  
Apr-18 9.7 33 249 No No No No  
12  Dec-17 
 
8.7 
 
35 
 
594 
 
No No NA No  
Jan-18 
 
9.0 
 
23 
 
712 
 
No No NA No  
Feb-18 
 
8.3 
 
16 
 
604 
 
No No NA PI  
Mar-18 
 
8.8  
 
25 
 
645 
 
No Yes 40mcg PI:A  
Apr-18 9.4 28 748 No Yes 40mcg PI:A  
13  Dec-17 
 
11 
 
24 
 
37 
 
No No NA No  
Jan-18 10.7 17 192 No No NA No  
 
Feb-18 
 
 
10.4 
 
 
- 
 
 
- 
 
 
Yes 
 
No 
 
300mg 
PI:V  
Mar-18 
 
11.5 
 
22 
 
99 
 
No No NA Yes  
Apr-18 10.7 24 159 
 
No No NA Yes  
14  Dec-17 
 
- 
 
- 
 
- 
 
     
Jan-18 - - -      
Feb-18 
 
17.2 
 
36 
 
219 
 
No No NA PI  
Mar-18 
 
13.2 
 
47 
 
202 
 
No No NA Yes  
      (continued) 
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(continued)     
Apr-18 12.8 51 173 No No NA yes  
15  Dec-17 
 
12.3 
 
50 
 
281 
 
No No NA   
Jan-18 
 
12.3 
 
37 
 
343 
 
No No NA   
Feb-18 
 
12.1 
 
51 
 
404 
 
No No NA PI  
Mar-18 
 
10.1 
 
52 
 
597 
 
No No NA Yes  
Apr-18 9.8 45 
 
471 No No NA No  
16  Dec-17 
 
8.3 
 
26 
 
716 
 
No No NA   
Jan-18 
 
9.8 
 
42 
 
808 
 
No No NA   
Feb-18 
 
9.7 
 
40 
 
707 
 
No No NA PI  
Mar-18 
 
10 
 
56 
 
793 
 
No No  Yes  
Apr-18 9.6 95 1075 No yes 60mcg PI:A  
17  Dec-17 
 
- 
 
- 
 
- 
 
     
Jan-18 
 
- 
 
- 
 
- 
 
     
Feb-18 
 
8.7 
 
19 
 
280 
 
No No NA PI  
Mar-18 
 
10.7 
 
33 
 
309 
 
No No NA Yes  
Apr-18 - 23 253 No No NA   
18  Dec-17 
 
9.7 
 
16 
 
87 
 
No No NA   
Jan-18 
 
9.3 
 
16 
 
87 
 
No No NA   
Feb-18 
 
9 
 
23 
 
124 
 
No No NA PI  
Mar-18 
 
8.4 
 
15 
 
80 
 
Yes Yes 100mcg 
300mg 
PI:A 
PI:V 
 
Apr-18 9.1 14 68 Yes Yes 100mcg 
300mg 
PI:A 
PI:V  
? infec 
19  Dec-17 
 
8.3 
 
26 
 
716 
 
Yes No 300mg PI:V  
Jan-18 
 
9.8 
 
47 
 
808 
 
No No NA NA  
         
      (continued) 
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(continued)     
Feb-18 
 
9.7 
 
40 
 
707 
 
No No NA PI  
Mar-18 
 
10.0 
 
56 
 
793 
 
No No NA Yes  
Apr-18 9.6 95 1075 No No NA No  
20  Dec-17 
 
9.1 
 
13 
 
246 
 
No No NA   
Jan-18 
 
10.0 
 
11 
 
300 
 
No No NA   
Feb-18 
 
9.8 
 
45 
 
566 
 
No No NA PI  
Mar-18 
 
11.5 
 
17 
 
341 
 
Yes No 100mg PI:V  
Apr-18 12.5 36 524 No No NA Yes  
21  Dec-17 
 
10.7 
 
21 
 
307 
 
No No NA   
Jan-18 
 
10.4 
 
30 
 
267 
 
No No NA   
Feb-18 
 
10.6 
 
30 
 
529 
 
No No NA PI  
Mar-18 
 
10.2 
 
32 
 
297 
 
No No NA Yes  
Apr-18 9.7 25 296 No No NA No  
22  Dec-17 
 
11.0 
 
24 
 
384 
 
No No NA   
Jan-18 
 
9.6 
 
22 
 
303 
 
No Yes 100mcg   
Feb-18 
 
11.3 
 
596 
 
427 
 
No No NA PI  
Mar-18 
 
9.8 
 
18 
 
388 
 
Yes No 300mg PI:V  
Apr-18 10.3 27 480 No No NA Yes  
23  Dec-17 
 
9.9 
 
18 
 
161 
 
No No NA   
Jan-18 
 
12.0 
 
29 
 
123 
 
No No NA   
Feb-18 
 
11.1 
 
41 
 
246 
 
No No NA PI  
Mar-18 
 
9.1 28 439 No No NA No  
Apr-18 - - -     No  
Show 
        (continued) 
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  (continued)     
24  Dec-17 
 
11 
 
24 
 
37 
 
No No NA   
Jan-18 
 
10.7 
 
17 
 
19 
 
No No NA   
Feb-18 
 
10.4 
 
- 
 
- 
 
No No NA PI  
Mar-18 
 
11.5 
 
22 
 
99 
 
No No NA Yes  
Apr-18 10.7 24 159 No No NA Yes  
Note. PI-Protocol implemented; PI: A-Protocol implemented –Aranesp; PI: V Protocol 
implemented -Venofer.  
During the month of February 2018, when the protocols were first introduced,11 patients 
(45.8%) had a Hgb level below 10g/dL, and 13 (54%) had a level of 10g/dL and above, which is 
the targeted range. Forty-two percent or 10 dialysis recipients had a TSAT of 30% and above and 
11 patients (45.8%) had a TSAT below 30% and 3 (12.5%) had no results during the same 
month. Six of the dialysis recipients who had low TSAT levels also had Hgb level below 10g/dL 
which represents 25% of the patient census.  
The Aranesp and Venofer protocols, which are located in Appendix C and Appendix D 
respectively, were implemented by the nursing staff in February 2018. As of March 2018, eight 
(33.3 %) dialysis recipients had a Hgb level below 10g/dL, and 16 (66.6 %) had their Hgb levels 
above 10g/dL. Seven (29.1%) dialysis participants had TSAT 30% and above, sixteen (66.6%) 
had TSAT level below 30%, and one (4.1%) participant had no laboratory results recorded. 
Finally, in the month of April, 2018, eight (33.3%) dialysis recipients had Hgb levels below 
10g/dL, 13 (54.1 %) had a Hgb level above 10g/dL and three (12.5%) had no laboratory results 
available. Of the participants, nine (37.5 %) had TSAT above 30%, thirteen (54.1%) had TSAT 
levels below 30% and two (8.3%) patients had no TSAT results available. TSAT and Hgb values 
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were not available for patients who missed their complete blood count (CBC) and iron profile 
blood draws at the clinic or those who were hospitalized.  
If the TSAT level is above the target of 30-50% and ferritin which is iron storage is 
above 100-500ng/ml, the Venofer protocol should not be implemented. However, if the TSAT is 
below 30% and the Ferritin is below 100ng/ml, the Venofer protocol must be implemented. In 
March after a full month of having the protocols implemented 10 dialysis participants had their 
TSAT below 30%; eight (33.3%) of those participants had the Venofer protocol applied resulting 
in five (20.8%) of them with improved TSAT to target level in April. The two (8.3%) remaining 
participants who needed Venofer did not receive it, one (4.1%) received Aranesp instead and the 
other received no treatment; reasons were not documented for this observation. In April, only 
four (16.6%) dialysis participants had a TSAT below 30%, three (12.5%) of those participants 
had the Venofer protocol applied and one (4.1%) had the Aranesp protocol applied instead. 
If the Hgb level is at 10-11g/dL which is the target range, the Aranesp protocol should 
not be implemented. However, if Hgb is outside this range then the Aranesp protocol must be 
implemented. In March, after the implementation of the Aranesp protocol, eight dialysis 
participants or 33.3% had Hgb levels below 10g/dL but only five (20.8%) of them received the 
Aranesp per protocol. It is unknown why the other three (12.5%) did not receive Aranesp as 
needed. Of the five participants who received the Aranesp protocol four had improved Hgb 
levels to the target. In April, seven of the participants had Hgb levels below 10g/dL and should 
have the Aranesp protocol implemented however, only four of them had the protocol applied for 
unknown reasons. 
Overall, the protocol implementation was effective; before implementation of the anemia 
management protocols only 4 of the 12 dialysis participants who needed Aranesp did receive it 
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which is 33.3% and only 4 of the 11 dialysis participants who needed Venofer received it which 
is 36.3%. Similarly, after implementation of the anemia management protocols, 9 of the 15 
participants who needed Aranesp received it, which is 60% of the dialysis participants indicating 
a 26.7% increase in Aranesp administration by using the Aranesp protocol. After the 
implementation of the Venofer protocol, 8 dialysis participants needed Venofer and 6 received it 
which is 75% of the dialysis participants indicating 38.7 % increase by using the Venofer 
protocol. Finally, more than 50% of the participants demonstrated accuracy in the return 
demonstration of Aranesp and 100% verbalized understanding of the written materials available 
in both Spanish and English after watching the video and receiving an anemia pamphlet. The 
ultimate goal to improve Hgb levels was obtained and by the end of April 2018, 62.5 % of the 
dialysis participants had a minimum Hgb level of 10g/dL  
Discussion and Conclusions 
Findings Related to Evidence  
 
Anemia management protocols (AMPs) guide ESA and iron dosing for effective 
management of patients with CKD (Kliger et al., 2013). In four clinical trials conducted by major 
drug companies, Hgb was maintained using dosing algorithms and a dosing protocol 
(Charlesworth et al., 2014). The dosing algorithms were designed to achieve and maintain Hgb 
levels at the desired target. A retrospective observational study in 174 patients conducted over 6 
months implemented an Aranesp dosing anemia protocol. The results indicated that the use of an 
anemia management protocol resulted in decreased prescribing of Aranesp and iron while 
increasing patients target Hgb range to an acceptable level of 10-12g/dL (Charlesworth et al., 
2014). These results are comparative to the findings of the quality improvement project that the 
use of an anemia management protocol is effective in improving Hgb levels.   
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In a study related to PD conducted by Pirkle et al. (2014) 139 PD patients received 
Aranesp and intravenous iron for anemia management protocol. The study found that patients 
maintained stable Hgb levels between 10-12g/dL on the anemia management protocol using 
Aranesp and IV iron. This treatment intervention is inconsistent with the levels of the current 
KDIGO anemia management guidelines of maintaining Hgb at 10-11.5g/dL (Kliger et al., 2013). 
Similarly, in this project, dialysis participants who had the Aranesp protocol and Venofer iron 
protocol implemented had improvements in their Hgb and TSAT levels.  On the other hand, 
there was an exception of one participant who received the Venofer protocol who showed no 
improvement in TSAT over a 1-month period and three participants who received the Aranesp 
protocol did not show improvement in their Hgb levels over the same period. This may be 
attributed to patient disease process or poor response to iron and Aranesp if an infection is 
imminent, however patient vital signs and other parameters were not monitored to determine if 
the patients had a fever or infection. In addition, a longer monitoring period of two to three 
months would likely yield mature red blood cells and improved Hgb status.   
According to these results, Venofer therapy was the most favorable administration and 
this preference could likely be associated with the less expensive cost of Venofer when 
compared to Aranesp and its effectiveness in improving Hgb (Kliger et al., 2013). In addition, 
Kliger et al. (2013) state that for CKD patients, iron therapy has the potential to increase Hgb 
concentration and decrease ESA dose which could be a possible intent for the favorability results 
in administering Venofer 100% of the time. It is also important to note that the administration of 
Aranesp increased each month after the protocol implementation and the administration of 
Venofer remained consistent at 100% each month.       
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Protocol implementation involves the patient as a significant component of the 
intervention. Patient teaching is effective in enhancing patient care and is a significant aspect of 
the home dialysis patient (Schaepe & Bergjan, 2015). Smith and Zsorhar (2013) also stated that 
effective patient teaching methods includes computer-aid teaching, video education, 
demonstration, return demonstration, teach back or tell back, and written materials with pictures. 
Additionally, written materials created at a reading level for the general population combined 
with verbal health information significantly improved knowledge (Marcus, 2014). This was 
evident in the patients’ demonstration of the educational materials received through these 
medium. More than 50% of the participants demonstrated accuracy in the return demonstration 
of Aranesp and 100% verbalized understanding of the written materials available in both Spanish 
and English. The other 50% did not demonstrate 100% accuracy of Aranesp administration and 
received correction in administration.  
Implications for Practice  
 
Implementation and consistent utilization of the anemia management protocol was 
deemed effective in staff and patient learning. This ultimately resulted in improved knowledge 
and skills among staff and patients resulting in improved patient outcomes. These findings are 
relevant implications for practice and lessons learned. Anemia is a risk factor of mortality and 
morbidity in the CKD patient, and as a result, the role of anemia management in CKD is more 
focused on patient clinical outcomes of mortality, cardiovascular complications, quality of life 
and progression to ESRD (Horl,2013).  
In addition, staff feedback (Appendix I) indicated that the protocols were useful in the 
clinical practice since no protocol was previously available. One recommendation was that 
patients with the iPads should record themselves administering their Aranesp at home. The two 
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registered nurses and medical assistant stated they used the protocols and it did improve their 
knowledge on anemia management and understanding the goals of Hgb, TSAT and ferritin 
targets in the CKD patient who is receiving PD.  They also observed improvement in patient 
administration techniques after the patients watched the video and noted improvement in 
hemoglobin levels after the protocol implementation.   
Limitations of Project 
 
Several limitations were noted in this quality improvement project. Most identifiable is 
that the DNP student could not be present at all the interventions for observation. Secondly, there 
was a lack of accurate documentation of the patient interventions received. Specifically, patients 
received educational handouts and self-administered Aranesp with return demonstration, 
however, it was not documented on all the patients who received these interventions. 
Additionally, some patients who needed to have one of the protocols implemented did not 
receive the protocol for undocumented reasons. The charge nurse perceived that the patients who 
missed the protocols were an oversight by the less experience nurse. Other barriers to note is that 
this is a rural clinic and the nurses and MA are often out at the patients’ homes and not always at 
the clinic.  This is a barrier because the patient may only be available to attend the clinic on the 
days the nurses and MA are making home visits and as a result not able to get a lab draw that 
month. 
Recommended Sustainability  
A television was purchased with a DVD player and the educational DVD was obtained 
by the DNP student to maintain the sustainability of the patient education portion of this project. 
The DVD player was placed in the patient educational classroom which is also used as the 
waiting area. The handouts were ordered with an extra 50 copies available and information to 
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order these handouts at no additional cost was emailed to the clinic manager and the assistant 
manager. Finally, the protocols were uploaded to the general policy and procedure in the 
electronic medical record (EMR) and in each participant’s chart.  
Relevance to Nursing Practice for APRN With DNP 
 
As an advanced practice nurse with a doctoral degree, there is great opportunity to impact 
the healthcare system by using advanced knowledge and skills to improve healthcare outcomes 
(American Association of Colleges of Nursing [AACN], 2006). The changes needed to create an 
impact in the clinic are unique to the abilities, expertise, and level of education of a doctoral 
prepared nurse according to the DNP essential of advanced nursing practice (AACN,2006). 
Despite the strong multidisciplinary team at the clinic, no one is educationally or clinically 
prepared to develop or implement these changes as an APRN with DNP. Developing and 
implementing an anemia management protocol using evidence-based clinical guidelines to 
improve patient outcomes and quality of care is unique to the DNP essential of clinical 
scholarship and analytical methods for evidence-based practice AACN (2006) and is an 
exceptional role of the DNP.  Engaging members of the healthcare team in the process to make 
valuable contributions to the quality improvement project is also imperative to the leadership 
role. These expert measures are consistent with the unique role of the DNP as indicated by the 
DNP essentials of interprofessional collaboration for improving patient and population health 
outcomes (AACN, 2006).  
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Appendix A: Project Approval Letter 
 
   
  
 
 
November 15, 2017 
 
  
 
To Whom It May Concern: Anemia management quality improvement project 
 
Kenisha Marajah has my permission to conduct a Doctor of Nursing Practice (DNP) 
project for UIW with staff and providers at Innovative Dialysis Solutions (IDS) at Home. 
I am aware that the project involves reviewing medical records pertinent to her project 
development. 
 
The purpose of the quality improvement project will be to improve patient teaching and 
improve staff management of anemia using evidence-based guidelines. I support this 
project entitled, "Anemia management in the adult dialysis patient". 
 
I can be contacted at 2795 Bulverde Road (FM 1863) Bulverde, TX 78163 or 315 N 
San Saba #102, San Antonio, TX 78207 at 210-277-1418 for further information. 
Sincerely, 
 
Clinical Manager IDS) 
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Appendix B: Staff Anemia Questionnaire (pre-test & post-test) 
 
1. How do you identify yourself? 
a. MD or Nurse Practitioner 
b. Clinical Manager or Charge Nurse 
c. Registered Staff Nurse or Medical Assistant 
d. Other 
 
2. What is anemia?  
a. More red blood cells than normal 
b. Less red blood cells than normal 
c. I don’t know 
d. Other 
 
3. What is the acceptable clinical value for hemoglobin in the chronic kidney disease 
(CKD) patient? 
a. 9-10g/dL 
b. 10-11g/dL 
c. 10-12g/dL 
d. I don’t know  
 
4. How does kidney failure cause anemia? 
a. It does not  
b. The kidneys fail to produce erythropoietin 
c. The patient loose blood when their kidney fails 
d. I don’t know 
 
5. How is anemia usually treated in the CKD patient? 
a. Oral iron 
b. IV iron and an erythropeisis agent  
c. It cannot be treated   
d. I don’t know  
 
6. What are the two common Erythropoiesis-stimulating agents (ESAs) used to treat 
anemia in CKD? 
a. Vitamin B 12 and Folate 
b. Venofer and Iron 
c. Epogen and Aranesp 
d. I don’t know  
 
7. What are the two common iron therapies used to treat anemia in CKD? 
a. Aranesp and Iron 
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b. Epogen and Aranesp 
c. Venofer and Ferrlecit 
d. I don’t know  
 
8. Do you use an anemia management protocol to treat anemia in the clinic? 
a. Yes 
b. No 
c. Sometimes 
d. I don’t know 
 
9. Do you have the time to teach patients how to administer their ESA? 
a. Yes 
b. No 
c. Sometimes 
10. How do you adjust the dose of ESA (Aranesp) and IV iron (Venofer)?  
 a. Clinical judgment 
 b. Evidence-based guidelines 
 c. Doctors order 
 d. Other 
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Appendix C: Staff Maintenance Therapy Aranesp (Darbepoetin) 
 
Hemoglobin (hgb) level should be maintained at 10-11g/dL  
For darbepoetin alfa (DPA): "titrate as necessary to maintain a target hgb of 10-11 g/dl not to 
exceed 11.5 g/dL".  
If the hemoglobin exceeds 11.5 g/dL, dose should be temporarily withheld until the hemoglobin 
begins to decrease, at which point therapy should be reinitiated at a dose of 25% below the 
previous dose. 
 If the hemoglobin increases by more than 1 g/dL in a 2-week period, the dose should be 
decreased by 25%. 
 If the increase in the hemoglobin is less than 1 g/dL over 4 weeks and iron stores are adequate, 
the dose of Aranesp may be increased by approximately 25% of the previous dose.  
If hemoglobin is 10.1g/dL -11.0 g/dl, no change in Aranesp dosage 
If hemoglobin is > 11g/dL, decrease Aranesp by 25% 
If hemoglobin is > 11.5 g/dL HOLD Aranesp 
If patient is at Aranesp lowest dose and need to be further decreased then administer the lowest 
dosage every 2 weeks. 
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Appendix D: Staff Venofer Dosing Protocol 
 
Patients with CKD on peritoneal dialysis (PD), to a target of serum ferritin > 100 ng/ml (up to 
500 ng/ml) and TSAT > 30% (up to 50%).  
KDIGO Clinical practice guidelines suggest treating patients with iron supplementation when 
TSAT < 30% and ferritin < 500 ng/ml if an increase in Hgb or reduction in ESA dose is desired.  
 
Test iron status frequently (TSAT and Ferritin) when monitoring response after a course of iron. 
 
 
Avoid administering IV iron to patients with active systemic infections. 
 
Venofer 300 mg (in 250 ml; 
over 1.5 hours)  
then 
Venofer 400 mg (in 250 ml; 
over 2.5 hours) 
2 doses of the 300mg 14 days apart;  
then  
[400 mg dose] after another 14 days 
That is Day 1 =300mg, Day 15 = 300mg then Day 29th = 400mg  
NOTES 
Peritoneal Dialysis Dependent - Chronic Kidney Disease (PDD-CKD) 300 mg for 2 doses 14 
days apart, as infusion diluted in a maximum of 250mL of 0.9% NaCl. over 1.5 hours, followed 
by 400 mg infusion over 2.5 hours 14 days later. 
That is Day 1 = 300mg, Day 15 = 300mg and Day 29th = 400mg  
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Appendix E: Patient Educational Handout
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Appendix F: Patient Education Video  
..\..\EBP 1\ARANESP\Aranesp patient video.mp4 
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Appendix G: Teach-Back Self-Evaluation- Post patient educational intervention 
 
Patient #:___________________________ Date: _____/_____ 
 
Patient # #  Items  
to do or  
remember 
Did patient perform correctly  
    Yes No 
 
 
 
 
 
Use stepwise process to: 
Wash hands thoroughly 
Clean injection site with 
alcohol wipe 
Push syringe barrel to 
match prescribed dose  
Pinch injection site and 
inject medication 
subcutaneously  
   
____________ 
_____________ 
 
_____________ 
 
_____________ 
 
 
____________ 
____________ 
 
____________ 
 
____________ 
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Appendix H: Demographics & Hemoglobin Levels 
 
Chart Review Form 
 
Chart #: ________ Patient’s Gender: (1) Male (2) Female 
 
 
Patient’s Age (years): (1)_______ (2) Not Documented 
 
 
Marital Status: Single______ Married____ Divorced ______Widowed________ 
 
 
Ethnicity: White ____ Hispanic_______Asian_____African American ____ Other 
 
 
Hemoglobin levels (December 2017) pre-in: Greater than 10_____ Less than 10_________ 
 
Hemoglobin levels (April 2018) post-in: Greater than 10_____ Less than 10________ 
 
TSAT levels (December 2017) pre-intervention: ________      
 
TSAT levels (April 2018) post intervention: ________       
 
Ferritin levels (December 2017) pre-intervention: ______    
 
Ferritin levels (April 2018) post-intervention: ______ 
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Appendix I: Project Feedback 
1.Were the protocols useful in your clinical practice? How so   
_____________________________________________________ 
2.What would you change about the anemia management protocols or patient education? 
________________________________________________________ 
3. Do you use the protocols? If no, why not 
_________________________________________________________ 
 
4. Did the protocols improve your knowledge on anemia management? 
___________________________________________________________________  
 
5. Have you observed any improvement in patient hemoglobin level after administering the 
patient educational materials (pamphlet and Video)? If so what improvement did you observe 
_____________________________________________________________________ 
6. Have you observed any improvement in patient administration technique after watching the 
video? If so what improvement did you observe 
_________________________________________________________________________ 
 
 
 
